[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pcsk9-inhibitor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pcsk9-inhibitor":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100592653","early-phase-1-a-multicenter-prospective-randomized-controlled-trial-to-evaluate-the-efficacy-of-pcsk-9-inhibitors-in-delaying-the-progression-of-calcified-aortic-valve-disease-100592653",false,"NCT06996223","A Multicenter, Prospective, Randomized Controlled Trial to Evaluate the Efficacy of PCSK-9 Inhibitors in Delaying the Progression of Calcified Aortic Valve Disease","Inclusion Criteria:\n\n* Voluntarily sign informed consent;\n* Age ≥18 years old, gender unlimited;\n* Patients with aortic stenosis diagnosed by echocardiography;\n* Combined with atherosclerotic cardiovascular disease or\n* hypercholesterolemia LDL-C≥4.9mmol\u002FL;\n* The blood lipids were not up to standard after the maximum tolerated dose of statins;\n\nExclusion Criteria:\n\n* Rheumatic aortic stenosis;\n* Previous use of PCSK9 inhibitors or allergy to PCSK9 inhibitors;\n* Left ventricular ejection fraction ≤35%;\n* Patients planned to undergo aortic valve replacement or TAVR in the near future;\n* Complicated with other severe valvular diseases;\n* Poor adherence to treatment and inability to take medication according to the trial protocol;\n* Pregnant and lactating women;\n* Combined with active malignant tumors, severe liver and kidney dysfunction and other life expectancy of less than 1 year;\n* Participants who are participating in other interventional clinical studies;\n* Patients who were judged by the investigator to be ineligible for participation in the trial","ALL","18 Years",{"count":18,"type":19},316,"ESTIMATED","INTERVENTIONAL",[22],"EARLY_PHASE1","The aim of this clinical trial is to understand whether the drug PCSK9 inhibitor can slow the progression of calcific aortic valve disease and to understand the safety of the drug.\n\nThe primary objective of the study was to evaluate whether PCSK9 inhibitors could delay the progression of aortic stenosis in patients with aortic stenosis.\n\nSecondary objectives: 1) To evaluate whether PCSK9 inhibitors can delay the progression of valve calcification in patients with aortic stenosis;2) To evaluate whether PCSK9 inhibitors can reduce long-term adverse events in patients with aortic stenosis;3) To evaluate the effect of PCSK9 inhibitors on circulating Lp(a) levels in patients with aortic stenosis.",[25,26,27],"Aortic Stenosis","PCSK9 Inhibitor","Calcified Aortic Valve Disease","NOT_YET_RECRUITING","2025-05-21",{"date":31,"type":32},"2025-05-30","ACTUAL",{"date":34,"type":19},"2025-06-01",{"date":36,"type":19},"2027-12-30",{"name":38,"class":39},"Nanfang Hospital, Southern Medical University","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":20,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":64},"100522541","phase-4-the-effect-of-early-administration-of-pcsk9-inhibitor-to-acute-ischemic-stroke-patients-associated-with-atherosclerosis-on-the-stroke-prognosis-and-lipid-profile-100522541","NCT06083961","The Effect of Early Administration of PCSK9 Inhibitor to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid Profile","The Effect of Early Administration of PCSK9 Inhibitor, Alirocumab to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid Profile, a Single Center Study, Registry Based, Pragmatic, Prospective Trial","Inclusion Criteria:\n\n* Non-cardioembolic Stroke\n* Acute Ischemic stroke within 7 days of symptom onset (confirmed by CT or MRI)\n* Age 19 and above\n* Significant stenosis associated with atherosclerosis in major intracranial \u002F extracranial vessels.\n* National Institutes of Health Stroke Scale(NIHSS) score of 15 or less at admission\n* Patients with the capacity to consent for participation in the clinical trial.\n\nExclusion Criteria:\n\n* Presence of high-risk factors for cardioembolism\n* Risk of ischemic stroke due to thrombosis from other causes\n* Patients with hemorrhagic stroke, brain tumors, or brain abscesses\n* Patients unable to take statins or PCSK9 inhibitors\n* Pre-stroke mRS score of 3 or higher\n* Severe liver failure (liver enzyme \\> 3 times the upper normal limit) or renal failure (serum Creatinine \\> 2mg\u002FdL or estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73m2)\n* Anemia (hemoglobin \\\u003C 8mg\u002FdL) or thrombocytopenia (platelet count \\\u003C 100K)\n* Uncontrolled diabetes not managed by medication or insulin\n* Pregnant or breastfeeding patients\n* Patients already receiving PCSK-9 inhibitors\n* Patients deemed inappropriate for participation in the clinical trial by the investigator for other reasons.","19 Years",{"count":49,"type":19},200,[51],"PHASE4","The goal of this clinical trial is to test the effect of proprotein convertase subtilisin\u002Fkexin type 9 (PCSK9 inhibitors) in acute ischemic stroke patients associated with atherosclerosis by investigating\n\n1. the change in lipid profile compared to baseline results\n2. the effects on prognosis of stroke The participants will be given PCSK9 inhibitor right after confirmation of acute ischemic stroke, and the investigators will compare the results to the control group, whom are acute ischemic stroke patients treated with conventional lipid lowering therapy, statin and\u002For ezetimibe.",[54,26],"Stroke, Acute Ischemic","2023-10-09",{"date":57,"type":32},"2023-10-16",{"date":59,"type":19},"2023-10-15",{"date":61,"type":19},"2026-11-15",{"name":63,"class":39},"Sun U. Kwon",1]